The new deal expands upon a years-long cooperative partnership that has included the development of the SOPHiA Hereditary Cancer Solution—an in vitro diagnostic (IVD) launched in 2016—which predicts the genetic susceptibility and risk for patients of developing hereditary breast and ovarian cancer.
The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.
Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
The two companies will look to develop a kitted NGS solution for the identification of biomarkers using blood samples collected from patients enrolled in clinical trials.
The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
News & Features
Breakthrough device designation is designed to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving FDA standards.
Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
News & Features
Once Genexus is validated, the automated platform could help accelerate access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories.